Τίτλος:
Somatic mutations of the tyrosine kinase domain of epidermal growth
factor receptor and tyrosine kinase inhibitor response to TKIs in
non-small cell lung cancer: An analytical database
Γλώσσες Τεκμηρίου:
Αγγλικά
Περίληψη:
Background: After the discovery of somatic mutations in the tyrosine
kinase domain (exons 18-24) of the epidermal growth factor receptor
(EGFR) correlating with responses of non-srnall cell lung cancer (NSCLC)
to the tyrosine kinase inhibitors (TKIs) gefitinib and erlotinib, there
has been increasing interest in utilizing this molecular marker for
treatment selection. We aimed to analytically catalogue the Mutational
spectrum of somatic Mutations in EGFR and format a database allowing
correlation of specific mutations with clinico-pathologic factors and
response to TKIs.
Methods: A computerized search of MEDLINE (January I 2004 to,June 30,
2007) was performed to identify articles reporting on NSCLC patients
harboring somatic mutations in EGFR. Demographic, clinico-pathologic,
Mutational, and response data were extracted and tabulated.
Results: A total of 202 eligible articles were identified. We report
data on 12,244 patients with 3381 somatic EGFR mutations. The majority
Of mutations have been reported on only one occasion (158 of 254,
62.2%), and only nine Mutations occur at a rate of L858R and
delE746-A750 account for 32.84% and 24.28% of all mutations,
respectively; with 50% of mutations being exon 19 deletions or
“deletional-insertions.” There is a clear association between the
presence of Mutations and response to TKI.
Conclusions: We have generated a free access, nonprofit online
analytical database of somatic EGFR mutations in NSCLC. Cumulative
information will be made available through a routine update of both
database tables and associated graphical representations. Direct updates
and Submissions through the online site (www.somaticmutations-EGFR.org)
are encouraged, as are comments and suggestions.
Συγγραφείς:
Murray, Samuel
Dahabreh, Issa J.
Linardou, Helena and
Manoloukos, Menelaos
Bafaloukos, Dimitrios
Kosmidis, Paris
Περιοδικό:
Journal of Thoracic Oncology
Εκδότης:
EXCERPTA MEDICA INC-ELSEVIER SCIENCE INC
Λέξεις-κλειδιά:
gefitinib; erlotinib; non-small cell lung cancer; smoking;
adenocarcinoma
DOI:
10.1097/JTO.0b013e31818071f3
